Viragen Inc said it is sponsoringclinical studies of Human Leukocyte Interferon, Alpha, in thetreatment of renal cell carcinoma and bladder cell carcinoma.    The Food and Drug Administration approved human trials will be conducted on at least 30 patients, male and female foreach cancer type. Reuter&#3;